The Experts below are selected from a list of 1473459 Experts worldwide ranked by ideXlab platform
George K - One of the best experts on this subject based on the ideXlab platform.
-
Maternal serum Alpha-Fetoprotein levels in chorioangiomas.
American Journal of Perinatology, 1994Co-Authors: Khong Ty, George KAbstract:: It has been suggested that chorioangiomas should be added to the list of causes of elevated maternal serum Alpha-Fetoprotein levels. We undertook a review of maternal serum Alpha-Fetoprotein levels in chorioangiomas histologically diagnosed in our department, and a review of the literature. Maternal serum Alpha-Fetoprotein level was elevated in only 1 of our 11 cases of chorioangioma. To date, there have been 14 case reports of chorioangiomas in which maternal serum Alpha-Fetoprotein levels have been recorded; 12 of these were associated with elevated maternal serum Alpha-Fetoprotein levels. We consider that, although chorioangiomas may be a cause of elevated maternal serum Alpha-Fetoprotein levels, it is likely to be infrequently a cause of such elevations in our population.
Joseph B Lessing - One of the best experts on this subject based on the ideXlab platform.
-
Doppler velocimetry of the umbilical artery as a predictor of pregnancy outcome in pregnancies characterized by elevated maternal serum Alpha-Fetoprotein and normal amniotic fluid Alpha-Fetoprotein
Fetal Diagnosis and Therapy, 1997Co-Authors: Ariel J Jaffa, Joseph Har-toov, R. Amster, Cyril Legum, Yuval Yaron, Joseph B LessingAbstract:Objective: Women with elevated maternal serum Alpha-Fetoprotein (MSAFP) and normal amniotic fluid Alpha-Fetoprotein (AFAFP) are at an increased risk of an adverse pregnancy outcome.
Hye J. Heo - One of the best experts on this subject based on the ideXlab platform.
-
First-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease
American journal of obstetrics and gynecology, 2019Co-Authors: Cheryl Dinglas, Nur Afsar, Elizabeth Cochrane, Jay Davis, Sara Kim, Meredith Akerman, Matthew Wells, Martin Chavez, Kimberly Herrera, Hye J. HeoAbstract:Background While elevated second-trimester maternal serum alpha fetoprotein has been associated with adverse pregnancy outcomes, the utility of first-trimester maternal serum alpha fetoprotein in predicting these outcomes is limited. Some laboratories have been including maternal serum alpha fetoprotein as part of the first-trimester analyte screening for aneuploidy and preeclampsia, offering its potential utility in predicting pregnancy outcomes. Objective Our primary objective was to determine the association between elevated first-trimester maternal serum alpha fetoprotein and preeclampsia as well as ischemic placental disease (a composite of preeclampsia, fetal growth restriction, and/or placental abruption). Secondary outcomes included early-onset preeclampsia requiring delivery at Study Design An institutional review board–approved multisite retrospective cohort study was performed including all patients with first-trimester maternal serum alpha fetoprotein as part of routine first-trimester aneuploidy screening from April 2015 through January 2017. Pregnancies with multiple gestations, known structural or chromosomal abnormalities, known malignancy, and incomplete delivery records were excluded. Delivery records were reviewed for baseline characteristics and adverse pregnancy outcomes. The optimal cutoff point for first-trimester maternal serum alpha fetoprotein to predict these outcomes was assessed, and an elevated maternal serum alpha fetoprotein was considered >2.0 multiple of the median. A Fisher exact test and odds ratios were used to determine the association between elevated first-trimester maternal serum alpha fetoprotein and adverse pregnancy outcomes. Spearman correlation coefficient assessed the relationship between first- and second-trimester maternal serum alpha fetoprotein. Results Of 1478 patients with first-trimester maternal serum alpha fetoprotein, 1280 had complete records available for review (86.6%). There was no association demonstrated between elevated first-trimester maternal serum alpha fetoprotein (>2.0 multiple of the median) and the primary outcome, overall preeclampsia (5.8% vs 4.6%, odds ratio, 1.29, 95% confidence interval, 0.58–2.91). However, there was an increased incidence of ischemic placental disease, 15.8% vs 7.7% (odds ratio, 2.26, 95% confidence interval, 1.33–3.87) in those with an elevated alpha fetoprotein. Also, elevated first-trimester maternal serum alpha fetoprotein was associated with a higher incidence of fetal growth restriction (7.5% vs 2.3%, odds ratio, 3.40, 95% confidence interval, 1.56–7.42) and preterm birth (18.3% vs 10.3%, odds ratio, 1.95, 95% confidence interval, 1.18–3.21). Also, a positive correlation between first- and second-trimester maternal serum alpha fetoprotein was demonstrated (rho = 0.46, P Conclusion Elevated first-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease, fetal growth restriction, and preterm birth. This suggests that elevated maternal serum alpha fetoprotein may help to identify high risk pregnancies as early as the first trimester of pregnancy. Future studies are necessary to determine whether the addition of first-trimester maternal serum alpha fetoprotein to existing algorithms can improve the early detection of ischemic placental disease.
M I Evans - One of the best experts on this subject based on the ideXlab platform.
-
Alpha-Fetoprotein.
Current opinion in obstetrics & gynecology, 1991Co-Authors: Arie Drugan, E Dvorin, J E Obrien, M P Johnson, M I EvansAbstract:The past year has seen major challenges to existing maternal serum Alpha-Fetoprotein testing protocols for both neural tube defects and chromosomal anomalies. These challenges are reviewed along with the physiology of Alpha-Fetoprotein; the use of amniocentesis, ultrasonography, and additional serum markers in women with elevated Alpha-Fetoprotein levels; and epidemiologic implications of maternal serum Alpha-Fetoprotein screening.
Khong Ty - One of the best experts on this subject based on the ideXlab platform.
-
Maternal serum Alpha-Fetoprotein levels in chorioangiomas.
American Journal of Perinatology, 1994Co-Authors: Khong Ty, George KAbstract:: It has been suggested that chorioangiomas should be added to the list of causes of elevated maternal serum Alpha-Fetoprotein levels. We undertook a review of maternal serum Alpha-Fetoprotein levels in chorioangiomas histologically diagnosed in our department, and a review of the literature. Maternal serum Alpha-Fetoprotein level was elevated in only 1 of our 11 cases of chorioangioma. To date, there have been 14 case reports of chorioangiomas in which maternal serum Alpha-Fetoprotein levels have been recorded; 12 of these were associated with elevated maternal serum Alpha-Fetoprotein levels. We consider that, although chorioangiomas may be a cause of elevated maternal serum Alpha-Fetoprotein levels, it is likely to be infrequently a cause of such elevations in our population.